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Abstract 
Background and Purpose: Despite treatment with oral anticoagulants patients with non-valvular atrial 
fibrillation (AF) may experience ischemic cerebrovascular events. The aims of this case–control study in 
patients with AF were to identify the etiology of and the risk factors for cerebrovascular ischemic events 
occurring during non-vitamin K antagonists (NOACs) therapy for stroke prevention. 
Methods: Cases were consecutive patients with AF who had acute cerebrovascular ischemic events during 
NOACs treatment. Controls were consecutive patients with AF who did not have cerebrovascular events 
during NOACs treatment.  
Results: Overall, 713 cases 641 ischemic strokes and 72 TIAs; median age 80.0 years, Interquartile Range 
(IQR) 12; median NIHSS on admission 6.0 IQR 10 and 700 controls (median age 72.0 years, IQR 8) were 
included in the study. Recurrent stroke was classified as cardioembolic in 455 cases (63.9%) according to the 
A-S-C-O-D classification. On multivariable analysis, off-label low dose of NOACs (OR 3.18; 95% CI 1.95-
5.85), atrial enlargement (OR 6.64; 95% CI 4.63-9.52), hyperlipidemia (OR 2.40; 1.83-3.16) and 
CHA2DS2VASc score (OR 1.72 for each point increase; 95% CI 1.58-1.88) were associated with ischemic 
events. Among the CHA2DS2VASc components, age was older and presence of diabetes, congestive heart 
failure and history of stroke or TIA more common in patients who had acute cerebrovascular ischemic 
events. Paroxysmal AF was inversely associated with ischemic events (OR 0.45; 0.33-0.61). 
Conclusions: In patients with AF treated with NOACs who had a cerebrovascular event, mostly but not 
exclusively of cardioembolic etiology, off-label low dose, atrial enlargement, hyperlipidemia and high 
CHA2DS2VASc score were associated with increased risk of cerebrovascular events. 
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Introduction 
Clinical trials on the prevention of stroke in patients with atrial fibrillation (AF) have consistently shown a 
benefit associated with oral anticoagulant therapy. Despite an adequate treatment with vitamin K antagonists, 
some patients with AF still suffer ischemic cerebrovascular events (1). Non-vitamin K antagonist oral 
anticoagulants (NOACs) are currently recommended as the preferred anticoagulant strategy for patients with 
non-valvular AF, given their more favorable risk benefit profiles over warfarin (2-4).  
The aims of this multicenter case–control study in patients with AF on NOACs for stroke prevention were to 
identify the etiology of and the risk factors for cerebrovascular ischemic events which occurred during 
therapy with NOACs. 
 
Methods 
The data that support the findings of this study are available from the corresponding author upon reasonable 
request. 
Causes and risk factors of cerebral ischemic events in patients with non-valvular atrial fibrillation treated 
with NOACs for stroke prevention (ReNo) was a multicenter unmatched case-control study performed 
between January 2016 and June 2018. Consecutive patients with AF who experienced an acute ischemic 
stroke and had been prescribed NOACs (dabigatran, apixaban, rivaroxaban or edoxaban) for stroke 
prevention were included in the study. These patients, identified as cases, were enrolled in 37 Stroke Units 
across Europe, North America and Asia. Controls were patients with AF who had been taking NOACs for 
stroke prevention for more than 1 month and did not suffer cerebrovascular events after the initiation of 
anticoagulant therapy. Controls were consecutive outpatients attending four European Anticoagulant 
Therapy Services Torino (358 patients), Perugia (190 patients), Varese (94 patients), Kyiv (46 patients), 
and three stroke unit follow-up services (12 patients).  
Cases who had suspended anticoagulant therapy at least 24 h before the cerebrovascular event for any 
reasons and patients who did not guarantee compliance were excluded. To verify compliance, the patients 
and family members were asked how the prescribed anticoagulant was taken.  
The study was approved by the pertinent institutional review boards, if required. Informed consent was 
obtained from all patients. 
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Risk factors  
For cases and controls, data on known stroke risk factors were collected as following: age, gender, history of 
hypertension (blood pressure higher than 140/90 mmHg at least twice before acute stroke or already under 
treatment with antihypertensive drugs), history of diabetes mellitus (fasting glucose level higher than 126 
mg/dL pre-prandial on two examinations, glucose level higher than 200 mg/dL postprandial, or HbA1c 
higher than 6.5%, or under antidiabetic treatment), current cigarette smoking, hyperlipidemia (total 
cholesterol higher than 200 mg/dL or triglyceride higher than 140 mg/dL or already under lipid lowering 
therapy), history of symptomatic ischemic heart disease (myocardial infarction, history of angina or previous 
diagnosis of multiple lesions on thallium heart isotope scan or evidence of coronary disease on coronary 
angiography), history of symptomatic peripheral arterial disease (intermittent claudication of presumed 
atherosclerotic origin; or ankle/arm systolic blood pressure ratio lower than 0.85 in either leg at rest, or 
history of intermittent claudication with previous leg amputation, reconstructive surgery, or angioplasty), 
alcohol abuse (more than 300 g per week), obesity (body mass index  higher than 30 kg/m2), or previous 
stroke/TIA. Likewise, baseline variables were obtained for all patients including creatinine clearance 
(calculated by Cockcroft-Gault equation), type and duration of NOAC treatment. The doses of NOACs were 
recorded and the reasons for prescribing low doses were also collected. Low doses of NOACs were 
considered off-label in the absence of the recommended clinical and laboratory criteria for dose reduction (5-
8). Low dose of dabigatran was considered as labelled for elderly patients (age ≥80 years), patients with 
moderate renal impairment (creatinine clearance 30–49 mL/min) and those with concomitant use of 
interacting drugs (e.g., verapamil). Low dose of rivaroxaban was considered as labelled for patients with 
moderate or severe renal impairment (creatinine clearance 15–49 mL/min). Low dose apixaban was 
considered as labelled for patients with at least two of the following: age ≥80 years, weight ≤60 kg, or serum 
creatinine ≥1.5 mg/dL. Low dose edoxaban was considered label in patients with moderate or severe renal 
impairment (creatinine clearance 15–49 mL/min), in those with concomitant use of interacting drugs and in 
those with a weight ≤60 kg. 
Non-valvular AF was classified as: 1) paroxysmal: associated with episodes terminating spontaneously 
within seven days; 2) persistent: associated with episodes lasting more than seven days or requiring 
pharmacological and/or electrical cardioversion; 3) permanent: persisting for more than one year, either 
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because cardioversion failed or was not pursued (9). For the purpose of the present study, AF was classified 
into two types: paroxysmal or sustained (persistent or permanent).  
For cases, the CHA2DS2VASc score (2 points for history of stroke or age older than 75 years and 1 point 
each for congestive heart failure, hypertension, diabetes, vascular disease, age between 65 to 74 years and 
female sex) was calculated before the cerebrovascular event. For controls, the CHA2DS2VASc score was 
calculated at the time of anticoagulant therapy initiation. 
A trans-thoracic echocardiogram (TTE) was performed within 7 days from stroke onset in cases and during 
follow up in controls by a local cardiologist using a standardized protocol. Patients were imaged in the left 
lateral decubitus. Images were obtained using a 3.5 MHz transducer, at a depth of 16 cm in the parasternal 
(standard long- and short-axis images) and apical views (standard long-axis, two- and four- chamber 
images). Standard two-dimensional and color Doppler data, triggered to the QRS complex, were saved in 
cine loop format. Pulsed and continuous wave Doppler data were also stored digitally. Left atrial 
enlargement was defined following the American Society of Echocardiography guidelines and the European 
Association of Echocardiography (10,11). 
 
Characteristics of patients with acute stroke or TIA during NOACs treatment 
On admission, in all cases with acute ischemic stroke or TIA, stroke severity was assessed using the National 
Institutes of Health Stroke Scale (NIHSS). A non-contrast cerebral computed tomography (CT) or cerebral 
magnetic resonance imaging (MRI) scan was performed on admission in all patients to exclude intracranial 
hemorrhage. All patients underwent angio-CT or MRI scan to assess intracranial stenosis and an 
ultrasonography examination of the carotid and vertebral arteries (12-14). Occlusion of an artery in the 
territory of the infarct was defined as an absence of flow and the presence of a visible plaque. For the latter, 
the occlusion was considered to be atherosclerotic. 
For the causes of stroke, the A-S-C-O-D classification was used (15,16). A-S-C-O-D phenotyping (A: 
atherosclerosis; S: small-vessel disease; C: cardiac pathology; O: other causes; D: dissection) assigns a 
degree of likelihood of causal relationship to every potential disease (1 for potentially causal, 2 for causality 
is uncertain, 3 for unlikely causal but the disease is present, 0 for absence of disease, and 9 for insufficient 
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workup to rule out the disease) commonly encountered in ischemic stroke describing all underlying diseases 
in every patient.  
White matter changes [leukoaraiosis defined on the first CT (or MR) examination as ill-defined and 
moderately hypodense (or hyperintensity on T2-weighted on MR) areas larger than 5 mm according to 
published criteria] were investigated (17). Leukoaraiosis in the deep white matter was dichotomized into 
absent versus present. 
 
Statistical analysis 
The aims of the unmatched analyses were to identify predictors of ischemic events. Univariate tests (2 test 
or Fisher’s exact test with Yate’s correction when appropriate) were used to compare patients with ischemic 
events (cases) with controls, regarding risk factors for stroke. Multivariable logistic regression analysis was 
performed to identify independent predictors for ischemic events. The variables included in this latter 
analysis were: CHA2DS2VASc score (separately as a continuous variable or including the risk factors within 
the score excluding the CHA2DS2VASc score), hyperlipidemia, alcohol abuse, paroxysmal AF, atrial 
enlargement and dose of NOACs. The variables low dose and off-label low dose were inserted into the 
multivariable model separately. Moreover, a sensitivity analysis after matching for age was performed. 
Data were analyzed with the SPSS/PC Win package 25.0.  
Sample size calculation. 
For this unmatched case-control study, it was assumed that at least 15% of controls would have had the risk 
factor with the lower incidence. In order to detect a minimum odds ratio of 1.5 with a power of 80% and an 
alpha risk of 5%, it was calculated that a total of 1,308 patients would have been needed (ratio controls/cases 
1:1) (18).  
 
Results 
Characteristics and causes of cerebrovascular events occurring during anticoagulant therapy 
During the study period, 713 consecutive patients on NOACs were admitted for an acute cerebrovascular 
event (641 ischemic strokes and 72 TIAs). The median age of these patients was 80.0 years, Interquartile 
Range (IQR) 12 and median NIHSS on admission was 6.0, IQR 10. Atherosclerotic lesions were detected in 
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420 patients (58.9%): extracranial ICA stenosis 30-49% in 190 (26.6%), extracranial ICA stenosis 50% in 
95 (13.3%), vertebral/basilar artery stenosis 50% in 33 (4.6%), intracranial stenosis in the anterior 
circulation 30-49% in 26 (3.6%), intracranial stenosis in the anterior circulation 50% in 41 (5.7%) and 
stenosis in more than one location in 38 patients (5.3%). Leukoaraiosis was found in 404 patients (56.7%). 
The index event occurred after an average of 14.4 months from initiation NOACs. 
Concerning the causes of the index events, 455 (63.9%) were considered cardioembolic strokes, according to 
A-S-C-O-D classification (Table 1).  
 
Predictors of cerebrovascular ischemic events during anticoagulant therapy  
The 713 cases were compared to a control group of 700 controls (median age 72.0 years, IQR 8). The 
characteristics of cases and controls are summarized in Table 2.  
On univariable analysis, cases with ischemic events were older, had a higher prevalence of vascular risk 
factors and atrial enlargement on TTE. Among the cases, 317 (44.5%) were treated with low doses of 
NOACs compared to 207 (29.6%) of controls. Of the 317 cases treated with low doses, 111 (35.0%) were 
treated with off-label low doses compared to 53 of the 207 controls (27.5%) treated with off-label low dose. 
Of the 111 cases treated with off-label low dose, 38 were treated with low dose because of “fear” of 
bleeding, 10 had history of bleeding, 7 were prescribed concomitant antiplatelet therapy and 46 for other 
causes (cost of the drug, recurrent falls, amyloid angiopathy, anemia, history of cancer, age, 
misinterpretation of the patient, preference of the patient, gastro-intestinal discomfort and hypertension); in 
10 patients, the cause remains unknown. Of the 53 controls treated with off-label low dose, 6 were treated 
with off-label low dose because of “fear” of bleeding, 10 had history of bleeding, 6 were prescribed 
concomitant antiplatelet therapy and 31 for other causes (recurrent falls, amyloid angiopathy, anemia, history 
of tumor, age, misinterpretation of the patient, preference of the patient, gastro-intestinal discomfort and 
hypertension).  
The results of multivariable and the sensitivity analyses are reported in Table 3. Patients treated with off-
label low doses and the presence of atrial enlargement, especially when severe, had a higher risk of ischemic 
events (OR 3.18; 95% CI 1.95-5.85, p=0.0001 and OR 6.64; 95% CI 4.63-9.52, p=0.0001, respectively). 
 9 
Additionally, CHA2DS2VASc score was associated with the occurrence of ischemic events (OR 1.72 for 
each point increase; 95% CI 1.58-1.88, p=0.0001). 
The characteristics of the patients with cerebrovascular events treated with low doses are summarized in 
Table 4. On multivariable analysis, CHA2DS2VASc score was associated with prescription of low dose 
NOACs (OR 1.35 for each point increase; 95% CI 1.20-1.52, p=0.0001). Low clearance of creatinine was 
associated with prescription of low dose NOACs (OR 0.98 for 1 ml/min increase; 95% CI 0.97-0.99, 
p=0.001).  
 
Discussion 
This unmatched case–control study showed that the main risk factor associated with an increased risk of 
ischemic cerebrovascular events was the administration of a low dose of NOACs. Specifically, 40-45% of 
the patients with ischemic events had been prescribed reduced doses of NOACs, and about 35% of these had 
been prescribed reduced off-label doses. The prescription of low dose was associated with higher 
CHA2DS2VASc score. The ORBIT II AF study reported that 1 in 7 patients treated with a NOAC were 
prescribed with a reduced dose of NOACs. Notably, more than half of the NOAC reductions were 
inconsistent with Food and Drug Administration (FDA) or European Medicines Agency (EMA) labeling and 
appeared to be unexplainably in patients with lower bleeding risk. In unadjusted analyses, patients receiving 
reduced NOAC doses had high crude adverse event rates, particularly those who should have received 
standard NOAC dosing. Although these results were consistent in adjusted analyses, the differences were not 
statistically significant (19).  
In the ReNo study, about 30% of the patients with cerebrovascular events had stroke due to causes other than 
cardio-embolism. Indeed, ischemic stroke in patients with AF is not thought to be exclusively cardiogenic. 
For this reason, in patients with stroke during anticoagulation therapy, the first step should be to confirm the 
etiology of the new event that more than often requires adjustments of the original treatment strategy. 
The presence of hyperlipidemia and the type of AF were independently associated with risks of 
cerebrovascular events in this study. Currently, these two variables are not represented in any international 
guideline risk scores for stroke in patients with AF. Therefore, it is plausible that by adding these two 
variables to currently used scores better predictions of risk could be obtained.  
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The ReNo study has the following limitations: 1) it was observational, and neither individual NOAC or their 
doses were randomized; 2) other pharmacological treatments besides NOACs were not investigated. 
Interactions between NOACs and other drugs are reported to be much lower than that of warfarin. 
Specifically, all currently available NOACs are substrates of the P-glycoprotein transporter, one-third of 
rivaroxaban is metabolized by the liver via CYP3A4/CYP3A5 and CYP2J2-dependent pathways and 
apixaban which has predominant non-renal clearance is eliminated via the CYP3A4, CYP1A2 and CYP2J2-
dependent pathways. Therefore, it is plausible that drug interactions may have interfered with the 
anticoagulant effect; 3) we excluded patients who could not guarantee adherence to the prescribed treatment 
regimen. As this information was provided by the patients themselves or the care-giver, a laboratory 
assessment of the anticoagulant status during the event might have been informative (20,21); 4) we did not 
collect data regarding any possible off-label overdose of NOACs; which has been reported in literature to be 
about 3% (22); 5) the bleeding risk of the patients included in the ReNo study remained unknown;  
6) Cases were collected from a number of Stroke Units in Europe, United States and Asia. Unfortunately, not 
all participating Stroke Units have an associated anticoagulant unit where the cases could have been 
collected. For this reason, we collected control data in 7 centers, all except one, associated to a Stroke Unit. 
The strengths of our study include its adequate sample size and its prospective design. Additionally, our 
analyses reflect real-life experiences and thus, may provide valuable information that could significantly 
reduce the incidence of ischemic events in patients with AF and stroke during NOAC therapy.  
Conclusion: In patients with AF treated with NOACs who had a cerebrovascular event, mostly but not 
exclusively of cardioembolic etiology, off-label low dose, atrial enlargement, hyperlipidemia and high 
CHA2DS2VASc score were associated with increased risk of cerebrovascular events. 
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Table 1: The etiology of cerebrovascular events in patients on NOACs for stroke prevention 
 
Etiology of stroke   ASCOD classification 
---------------------------------------------------------------------------------------------------------------------------- 
Cardioembolic (CE)   A(0,2,3)-S(0,2,3)-C1-O(0,2,3) 455   63.9% 
 
Other possible causes        233  32.7%  
-----------------------------------------------------------------------------------------------------------------------------  
Large Artery Disease (LAD)  A1,S(0,2,3)-C(2,3)-O(0,2,3)  24  3.3% 
Small Vessel Disease (SVD)  A(0,2,3)-S1-C(2,3)-O(0,2,3)  74  10.4% 
Other Causes (Other)   A(0,2,3)-S(0,2,3)-C(2,3)-O1  29  4.1% 
CE and LAD    A1-S(0,2,3)-C1-O(0,2,3)  65  9.1% 
CE and SVD    A(0,2,3)-S1-C1-O(0,2,3)  29  4.1% 
CE and Other    A(0,2,3)-S(0,2,3)-C1-O1  5  0.7% 
CE and LAD and SVD   A1-S1-C1-O(0,2,3)   3  0.4% 
LAD and SVD    A1-S1-C(2,3)-O(0,2,3)  4  0.6% 
---------------------------------------------------------------------------------------------------------------------------- 
ASCOD not collected        24  3.4% 
---------------------------------------------------------------------------------------------------------------------------- 
Total          713  100% 
 
 
 
  
 17 
Table 2. Characteristics of the cases and controls 
 
 
 
 
Cases 
(n=713) 
Controls 
(n=700) 
P 
Age (years), mean (median) 78.19.1 (80.0) 71.311.3 (72.0) 0.0001 
Females 375 (52.6%) 256 (36.6%) 0.0001 
Duration of therapy (mean, months) 14.412.0 29.121.0 0.0001 
 
Apixaban 
 
221 (31.0%) 
 
223 (31.8%) 
 
0.7 
Dabigatran 199 (27.9%) 160 (22.8%) 0.03 
Edoxaban 43 (6.0%) 26 (3.8%) 0.04 
Rivaroxaban 250 (35.1%) 291 (41.6%) 0.01 
 
Low dose NOACs 
 
317 (44.5%) 
 
207 (29.6%)  
 
0.0001 
Non-label low dose 111/317 (35.0%) 53/207 (25.6%) 0.03 
 
Creatinine clearance, mean (median) 
 
66.525.1 (63.0) 
 
76.325.9 (76.0) 
 
0.0001 
 
CHA2DS2VASc score4 
 
607 (85.1%) 
 
318 (45.4%) 
 
0.0001 
Hypertension 608 (85.3%) 562 (80.3%) 0.01 
Diabetes Mellitus 203 (28.5%) 120 (17.1%) 0.0001 
Hyperlipidemia 387 (54.3%) 192 (27.4%) 0.0001 
Alcohol abuse 101 (14.2%) 118 (16.8%) 0.01 
Current smoker 132 (18.5%) 116 (16.6%) 0.2 
Congestive heart failure 223 (31.3%) 148 (21.1%) 0.0001 
History stroke/TIA 339 (47.5%) 173 (24.7%) 0.0001 
Myocardial infarction 174 (24.4%) 148 (21.1%) 0.1 
Peripheral artery disease 123 (17.2%) 41 (5.9%) 0.0001 
Paroxysmal AF 177 (24.8%) 289 (41.3%) 0.0001 
 
Atrial enlargement on TTE 
Moderate 
Severe 
 
509/607 (83.9%) 
125/607 (20.6%) 
168/607 (27.7%) 
 
154/431 (35.7%) 
44/431 (10.2%) 
18/431 (4.2%) 
 
0.0001 
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Table 3: Multivariable and sensitivity analyses: predictive factors for ischemic stroke or TIA 
 
 
 
OR (95% CI) p Sensitivity 
analysis 
OR (95% CI) 
 
p 
Low dose NOACs 1.23 (0.93-1.65) 0.1 1.09 (0.72-1.63) 0.6 
Non-label low dose 3.18 (1.95-5.85) 0.0001 
 
3.56 (1.72-7.37) 0.001 
Hyperlipidemia 2.40 (1.83-3.16) 0.0001 2.82 (1.93-4.11) 0.0001 
Alcohol abuse 0.90 (0.62-1.30) 0.5 0.92 (0.57-1.48) 0.7 
Current smoker 1.19 (0.84-1.69) 0.3 1.25 (0.77-2.02) 0.4 
Paroxysmal AF 0.45 (0.33-0-61) 0.0001 0.37 (0.25-0.54) 0.0001 
CHA2DS2VASc score 1.72 (1.58-1.88) 0.0001 1.31 (1.16-1.48) 0.0001 
     
Age 1.09 (1.07-1.10) 0.0001   
Females 1.31 (0.99-1.73) 0.054   
Hypertension 0.83 (0.57-1.20) 0.3   
Diabetes Mellitus 1.80 (1.30-2.40) 0.0001   
Congestive heart failure 1.45 (1.06-1.93) 0.02   
History stroke/TIA 1.48 (1.12-1.96) 0.006   
Vascular disease (myocardial 
infarction and/or peripheral arterial 
disease) 
0.88 (0.65-1.19) 0.4   
 
In patients with TTE (n=1034): 
    
Atrial enlargement (yes/no) 6.64 (4.63-9.52) 0.0001 
 
4.05 (2.75-5.95) 0.0001 
No atrial enlargement 
Mild atrial enlargement 
Moderate atrial enlargement 
Severe atrial enlargement 
1 (Ref.) 
4.29 (2.71-6.77) 
8.06 (4.80-13.53) 
23.28 (12.58-43.07) 
0.0001   
 
 
Table 4. Characteristics of the patients with cerebrovascular events treated with low dose of NOACs 
 
 
 
 
Low dose 
(n=317) 
Standard dose 
(n=396) 
p 
Age (years), mean (median) 81.98.6 (82.0) 75.38.8 (76.0) 0.0001 
Females 200 (63.1%) 171 (43.2%) 0.001 
 
Creatinine clearance, mean (median) 
 
57.323.7 (55.0) 
 
70.723.5 (67.0) 
 
0.0001 
 
CHA2DS2VASc score4 
 
293 (92.4%) 
 
314 (79.3%) 
 
0.0001 
Hypertension 279 (88.0%) 329 (83.1%) 0.1 
Diabetes Mellitus 94 (29.6%) 109 (27.5%) 0.5 
Hyperlipidemia 161 (50.8%) 226 (57.1%) 0.08 
Alcoholism 34 (10.7%) 67 (16.9%) 0.01 
Current smoker 39 (12.3%) 93 (23.5%) 0.0001 
Congestive heart failure 105 (33.1%) 120 (31.5%) 0.5 
History of stroke/TIA 155 (48.9%) 183 (46.2%) 0.6 
Myocardial infarction 112 (35.3%) 138 (43.8%) 1.0 
Peripheral artery disease 43 (13.6%) 81 (20.4%) 0.02 
Paroxysmal AF 141 (44.5%) 148 (37.4%) 0.1 
Leukoaraiosis 200 (63.1%) 205 (51.8%) 0.001 
 
 
 
